ArticleMarine drugs2021
Comparative Metabologenomics Analysis of Polar Actinomycetes.
Article in Marine drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The Incredible Potential of Cave Actinobacteria in Finding New Antimicrobials and Bioactive Compounds.Chemistry & biodiversity · 2026Review
- Bacterial Espresso: Evaluating Accelerated Solvent Extraction for Selected Metabolite Recovery fromJournal of natural products · 2026Article
- Recent strategies and methodological advances for microbial natural product research in the post-genomics era.Archives of microbiology · 2025Review
- Assessing the effect of temperature onMicrobiology (Reading, England) · 2025Article
- Recent insights into actinobacteria research in antimicrobial resistance: a review.Molecular biology reports · 2025Review
- Last Decade Insights in Exploiting Marine Microorganisms as Sources of New Bioactive Natural Products.Marine drugs · 2025Review
- Genomic Insights and Antimicrobial Potential of NewlyMicroorganisms · 2025Article
- Article
- Physiology and comparative genomics of the haloalkalitolerant and hydrocarbonoclastic marine strain Rhodococcus ruber MSA14.Archives of microbiology · 2024Article
- Artificial intelligence for natural product drug discovery.Nature reviews. Drug discovery · 2023Review
- Prioritization of Microorganisms Isolated from the Indian Ocean SpongeMicroorganisms · 2023Article
- Micrococcus spp. as a promising source for drug discovery: A review.Journal of industrial microbiology & biotechnology · 2023Review
- Enhanced correlation-based linking of biosynthetic gene clusters to their metabolic products through chemical class matching.Microbiome · 2023Article
- The undiscovered biosynthetic potential of the Greenland Ice Sheet microbiome.Frontiers in microbiology · 2023Article
- Integrated Metabolomic-Genomic Workflows Accelerate Microbial Natural Product Discovery.Analytical chemistry · 2022Review
- Advancements in capturing and mining mass spectrometry data are transforming natural products research.Natural product reports · 2021Review
- Advances in decomposing complex metabolite mixtures using substructure- and network-based computational metabolomics approaches.Natural product reports · 2021Review
- Metabolomics and genomics in natural products research: complementary tools for targeting new chemical entities.Natural product reports · 2021Review
- Article
- Integrating perspectives in actinomycete research: an ActinoBase review of 2020-21.Microbiology (Reading, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Biosynthetic and chemical datasets are the two major pillars for microbial drug discovery in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.